Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$34.30 -0.6%	$29.76	$23.42 ▼ $62.58	$1.99B	0.73	662,530 shs	478,627 shs
CGON CG Oncology	$25.86 -2.4%	$24.04	$14.80 ▼ $40.47	$1.97B	0.86	837,930 shs	626,383 shs
IDYA IDEAYA Biosciences	$22.18 -0.4%	$18.94	$13.45 ▼ $44.42	$1.94B	0.04	1.03 million shs	862,850 shs
ZVRA Zevra Therapeutics	$9.13 -2.6%	$7.97	$4.20 ▼ $9.76	$499.23M	2.01	668,305 shs	533,628 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-0.09%	+21.37%	+10.90%	-28.50%
CGON CG Oncology	0.00%	-3.90%	+2.01%	-6.98%	-27.18%
IDYA IDEAYA Biosciences	0.00%	+2.07%	+28.13%	+19.38%	-43.72%
ZVRA Zevra Therapeutics	0.00%	-1.40%	+8.30%	+9.87%	+83.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	3.9345 of 5 stars	3.4	1.0	4.2	1.8	0.8	1.9
CGON CG Oncology	2.4409 of 5 stars	4.5	1.0	0.0	2.9	0.8	0.0
IDYA IDEAYA Biosciences	3.8503 of 5 stars	3.5	2.0	4.4	2.8	1.7	0.0
ZVRA Zevra Therapeutics	2.8565 of 5 stars	3.6	2.0	0.0	4.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	70.85% Upside
CGON CG Oncology	3.00	Buy	$58.22	125.14% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	144.69% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	144.09% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, AGIO, CGON, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
4/28/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00 ➝ $75.00
4/28/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/16/2025	CGON CG Oncology	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$23.00
3/31/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	53.64	N/A	N/A	$27.02 per share	1.27
CGON CG Oncology	$662K	2,977.61	N/A	N/A	($1.94) per share	-13.33
IDYA IDEAYA Biosciences	$7M	277.51	N/A	N/A	$12.10 per share	1.83
ZVRA Zevra Therapeutics	$40.59M	12.30	N/A	N/A	$1.71 per share	5.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.02	N/A	N/A	1,845.92%	-2.51%	-2.26%	7/30/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-26.74%	-25.54%	8/5/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	45.65	N/A	-342.63%	-159.54%	-51.50%	8/12/2025 (Estimated)

Latest ZVRA, AGIO, CGON, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
CGON CG Oncology	N/A	35.32	35.32
IDYA IDEAYA Biosciences	N/A	14.97	22.93
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CGON CG Oncology	26.56%
IDYA IDEAYA Biosciences	98.29%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
CGON CG Oncology	7.40%
IDYA IDEAYA Biosciences	2.50%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	84.47 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

ZVRA, AGIO, CGON, and IDYA Headlines

Recent News About These Companies

Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings

June 12 at 1:45 AM | americanbankingnews.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC

June 3, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by Analysts

May 27, 2025 | marketbeat.com

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 25, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LP

May 23, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

May 21, 2025 | marketbeat.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

May 20, 2025 | marketbeat.com

Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, AGIO, CGON, and IDYA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$34.30 -0.20 (-0.58%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$34.31 +0.01 (+0.03%)

As of 06/13/2025 05:50 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CG Oncology NASDAQ:CGON

$25.86 -0.64 (-2.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.92 +1.06 (+4.11%)

As of 06/13/2025 04:25 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

IDEAYA Biosciences NASDAQ:IDYA

$22.18 -0.10 (-0.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.96 -0.22 (-0.99%)

As of 06/13/2025 05:09 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Zevra Therapeutics NASDAQ:ZVRA

$9.13 -0.24 (-2.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.23 +0.10 (+1.10%)

As of 06/13/2025 07:05 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time